| Revenue growth | Q2 +24.7%, H1 +24.9%; ~16% Q2 constant currency |
|---|---|
| Margins | Q2 EBITDA margin 17.6% (+154bps); gross margin -197bps |
| Demand visibility | RoW +37% H1; Europe +23%; India +10% |
Growth
Q2 revenue +24.7%, EBITDA +36.6%, PAT +26.6%. H1 EBITDA +43.4%; H1 PAT +7.5% reported (+38.8% ex tax credit).
Outlook
No numeric guidance given. Management targets margin via richer mix, vertical integration, plant utilisation. Telangana has spare capacity.
Risks
Gross margin down 197bps YoY in Q2; employee and other costs rising. Four EU MDR certifications still pending before the 31-Dec-2027 deadline.
Investor Presentation filed with BSE, NSE: SMT. Summary written with AI assistance from the document.
Sahajanand Medical Technologies Ltd: key numbers
- Share price
- ₹487.75
- Market cap
- ₹4,958 Cr
- Revenue (annual)
- ₹1,210 Cr
- Net profit (annual)
- ₹65.28 Cr
- Promoter holding
- 36.20%
- FII holding
- 35.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sahajanand Medical Technologies Ltd
All →Sahajanand Medical Technologies Board Meeting Outcome
Sahajanand Medical Technologies' board appointed M/s Amit Jaste & Associates as Secretarial Auditor for FY 2026-27 to FY 2030-31. The appointment is subject to shareholder approval.
- Execution
- FY 2026-27 to FY 2030-31, five consecutive financial years, subject to shareholder approval
Sahajanand Medical Technologies Earnings Call Transcript: Key Takeaways
Record Q2 FY27: revenue up 24.7% to about ₹373 Cr, EBITDA up 36.6%, margin 17.6%. Reported H1 PAT up only 7.5% due to a prior-year one-off tax credit; ex-it about 39%. Gross margin fell 170 bps on traded-product mix.
Sahajanand Medical Technologies Acquisition Worth ₹7.33 Cr
Sahajanand Medical's Irish subsidiary approved up to USD 7,80,000 investment in SNP Medical Corp. This lifts its stake to 17.19%, a related-party deal at arm's length.
- Value
- ₹7.33 Cr
- Execution
- Tentatively completed by 31 March 2027
Sahajanand Medical Technologies Q2 FY27 Results: Net Profit ₹26.5 Cr, Up 26.8% YoY
Sahajanand Medical Technologies Ltd reported revenue from operations of ₹373.4 Cr (+24.7% YoY) and net profit of ₹26.5 Cr (+26.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹26.5 Cr · +26.8% YoY
Sahajanand Medical Technologies Legal & Regulatory
Sahajanand Medical Technologies received a GST DRC-01D recovery notice from Jharkhand tax authorities. The demand totals Rs. 34.29 lakh, which the company is contesting before appellate authorities.
- Value
- ₹0.34 Cr
Sahajanand Medical Technologies Credit Rating
CRISIL has upgraded Sahajanand Medical Technologies' long-term bank facility rating to CRISIL A-/Stable from BBB+/Stable. The upgrade reflects improved business risk, growing scale, and sustained profitability across its global stent manufacturing operations.
- Value
- ₹300.0 Cr